巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    TCR2 Therapeutics

    TCRR
    3.075
    0.110
    3.54%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・TCR2 Therapeutics - 延遲價格・最後更新於 06/07 7:25
    最高位
    3.080
    最低位
    2.890
    開市價
    --
    前收市價
    2.970
    成交量(千)
    16.87
    成交額(百萬)
    0.41
    買入
    3.050
    賣出
    3.070
    每手股數
    --
    市值(百萬)
    118.53
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    19.030 - 2.065
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    TCR2 Therapeutics
    證券代碼
    TCRR.US
    所屬板塊
    Biotechnology
    公司業務
    TCR2 Therapeutics Inc is a clinical-stage cell therapy company. It is engaged in developing a pipeline of novel T cell therapies for cancer patients suffering from solid tumors by powering the T cell receptor (TCR) with its proprietary, first-in-class TCR Fusion Construct T cells (TRuC-T cells). The company's TRuC-T cells specifically recognize and kill cancer cells by harnessing the entire TCR signaling complex, independent of human leukocyte antigens, which is effective in patients with solid tumors.
    發行量
    38546345
    公司總部
    100 Binney Street, Suite 710
    公司網址
    https://www.tcr2.com
    公司電話
    +1 617 949-5200
    暫無內容

    關於

    TCR2 Therapeutics(TCRR.US)所屬的行業板塊為Biotechnology。
    TCR2 Therapeutics Inc is a clinical-stage cell therapy company. It is engaged in developing a pipeline of novel T cell therapies for cancer patients suffering from solid tumors by powering the T cell receptor (TCR) with its proprietary, first-in-class TCR Fusion Construct T cells (TRuC-T cells). The company's TRuC-T cells specifically recognize and kill cancer cells by harnessing the entire TCR signaling complex, independent of human leukocyte antigens, which is effective in patients with solid tumors.
    詳細公司背景可參考: https://www.tcr2.com